Catch up on today’s top five analyst upgrades with this list compiled by The Fly:
1. Starbucks (SBUX) upgraded to Buy from Neutral at BTIG with analyst Peter Saleh saying the “faster-than-anticipated” pace of restaurant reopening, coupled with federal stimulus, should lead to upward earnings revisions.
2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Peter Welford saying the shares look “compelling” as they trade at a similar multiple to European pharma peers but with a “leading growth profile.”
3. AnaptysBio (ANAB) upgraded to Buy from Hold at Truist with analyst Joon Lee citing a “favorable” setup after the stock sold off by about 30% and with several catalysts upcoming over the next 12-18 months.
4. Solid Biosciences (SLDB) upgraded to Outperform from Market Perform at SVB Leerink with analyst Joseph Schwartz saying following report of the first functional data for Solid’s microdystrophin gene therapy as well as the clean safety for the 7th patient dosed with SGT-001, the analyst is “encouraged” by the totality of clinical improvements demonstrated particularly in older DMD patients with high baseline NSAA scores and believes there could be more “good things to come” for the company’s unique nNOSbinding form of microdystrophin.
5. Par Technology (PAR) upgraded to Buy from Neutral at Sidoti with analyst Anja Soderstrom saying that “record high” Brink bookings, strong backlog and pipeline strength set Par up for solid revenue growth and a path to profitability.
This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage,Click Here!
previous post